Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Sham-controlled, Double-masked, Multicenter Study Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

Trial Profile

A Randomized, Sham-controlled, Double-masked, Multicenter Study Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ocriplasmin (Primary)
  • Indications Eye disorders; Retinal disorders
  • Focus Therapeutic Use
  • Acronyms OASIS
  • Sponsors Oxurion; ThromboGenics
  • Most Recent Events

    • 16 Aug 2017 Results from this trial were presented at the 35th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS), according to a ThromboGenics media release.
    • 02 Nov 2016 Long-term efficacy results presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 07 Sep 2016 Results from this trial will be presented at the EURETINA Annual Conference 2016, according to a ThromboGenics media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top